Table 1. Clinicopathological characteristics of all patients according to NAC response.
| Characteristics | NAC | p-value | ||
|---|---|---|---|---|
| Non-response (n = 71) | Response (n = 34) | |||
| Age (mean, yr) | 50.4 ± 9.5 | 52.7 ± 9.5 | 0.255 | |
| > 50 | 36 (50.7) | 11 (32.4) | 0.077† | |
| ≤ 50 | 35 (49.3) | 23 (67.6) | ||
| HG | 0.060† | |||
| I | 7 (10.3) | 0 (0.0) | ||
| II, III | 61 (89.7) | 32 (100.0) | ||
| Unknown | 3 | 2 | ||
| ER | 0.004† | |||
| Positive | 44 (62.0) | 11 (32.4) | ||
| Negative | 27 (38.0) | 23 (67.6) | ||
| PR | 0.002† | |||
| Positive | 40 (56.3) | 8 (23.5) | ||
| Negative | 31 (43.7) | 26 (76.5) | ||
| HER-2 | 0.041† | |||
| Positive | 18 (29.0) | 17 (50.0) | ||
| Negative | 44 (71.0) | 17 (50.0) | ||
| No result | 9 | 0 | ||
| Ki67* | 0.187 | |||
| Low | 5 (7.1) | 5 (14.7) | ||
| Intermediate | 15 (21.4) | 3 (8.8) | ||
| High | 50 (71.4) | 26 (76.5) | ||
| No result | 1 | 0 | ||
| Clinical tumor size | 0.540 | |||
| ≤ 2 cm | 4 (5.6) | 3 (8.8) | ||
| > 2 cm | 67 (94.4) | 31 (91.2) | ||
| Clinical LN involvement | 0.592 | |||
| Positive | 53 (74.6) | 27 (79.4) | ||
| Negative | 18 (25.4) | 7 (20.6) | ||
NAC = neoadjuvant chemotherapy; HG = histologic grade; ER = estrogen receptor; PR = progesterone receptor; LN = lymph node.
*Ki67: low for < 10%, intermediate for 10–20, high for > 20% tumor cells. †The p-values with statistically significance or with a tendency to statistical significance.